Biogen Sheds $3 Billion in Value on Top Drug’s Patent Review

(Bloomberg) -- Biogen Inc. shed more than $3 billion in market value in the past two trading sessions as a patent review of its top drug Tecfidera Wednesday raised concerns over a potential generic...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.